Book a Meeting

Non-Fucosylated Anti-Human CTLA4 (27A) Therapeutic Antibody (CAT#: BioBet-1721ZP) Datasheet

Target
CTLA4
Isotype
IgG
Description
Non-Fucosylated Anti-Human CTLA4 (27A) is a glycosylation-modified therapeutic biobetter antibody.
Indication
Melanoma, metastatic
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CTLA4 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CTLA4
Full Name
Cytotoxic T-Lymphocyte Associated Protein 4
Alternative Names
Ipilimumab; yervoy; 477202-00-9; MDX-010; MDX-101; Yervoy; MDX-010; MDX-101; CTLA4; cytotoxic T-lymphocyte-associated protein 4; celiac disease 3, CELIAC3; cytotoxic T-lymphocyte protein 4; CD; CD28; CD152; GSE; ICOS; CD152 isoform; celiac disease 3;
Gene ID
1493
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
27A
Host
Humanized
Species Reactivity
Human
Description
This clone was generated using a stable CHO cell line with the FUT8 knockout gene. It was 100% non-fucosylated. In an in vitro cell-based ADCC assay, the afucosylated antibody clone showed significantly higher ADCC activity compared to its wild type version. The binding affinity of the non-fucosylated Fc variant antibody to Fc receptor is much higher than than the same antibody with fucosylated Fc. Robust and stable production of qualitative fully non-fucosylated therapeutic antibodies is achieved.
Indication
Melanoma, metastatic

Related Products

BetterBet™ Anti-CTLA4 Recycling Antibody (CAT#: AES-0622-ZP287)
Non-fucosylated Anti-Human CTLA4 (Ipilimumab) Therapeutic Antibody (CAT#: BioBet-181ZP)
BetterBet™ Anti-CTLA4 Half-Life Extended Antibody (CAT#: AES-0622-ZP1271)
Non-Fucosylated Anti-Human CTLA4 (BMS-986218) Therapeutic Antibody (CAT#: BioBet-1784ZP)
Highly Galactosylated Anti-CTLA4 (Ticilimumab (= Tremelimumab)) Antibody (CAT#: BioBet-GA-182ZP)
BetterBet™ Anti-CTLA4 On-Target Antibody (CAT#: AES-0622-ZP943)
Non-fucosylated Anti-Human CTLA4 (Ticilimumab) Therapeutic Antibody (CAT#: BioBet-182ZP)
Highly Galactosylated Anti-CTLA4 (Ipilimumab) Antibody (CAT#: BioBet-GA-181ZP)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany